Pharmaceutical compound
Clinical data | |
---|---|
Other names | XC-8 |
Legal status | |
Legal status |
|
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
Chemical and physical data | |
Formula | C10H13N3O2 |
Molar mass | 207.233 gยทmol |
3D model (JSmol) | |
SMILES
| |
InChI
|
Histamine glutarimide is an investigational new drug that is being evaluated for the treatment of cough in acute respiratory infection. It is a glutaminyl cyclase inhibitor.
References
- "Histamine glutarimide - EURRUS Biotech". AdisInsight. Springer Nature Switzerland AG.
- Clinical trial number NCT05273619 for "Efficacy and Safety of XC8, Film-coated Tablets, 40 mg in Patients With Dry Non-productive Cough Against Acute Respiratory Viral Infection" at ClinicalTrials.gov
- Romanova J, Chikina E, Rydlovskaya A, Pohl W, Renner A, Zeifman A, et al. (December 2020). "New Anti-Chemokine Oral Drug XC8 in the Treatment of Asthma Patients with Poor Response to Corticosteroids: Results of a Phase 2A Randomized Controlled Clinical Trial". Pulmonary Therapy. 6 (2): 351โ369. doi:10.1007/s41030-020-00134-5. PMC 7671956. PMID 33095411.
This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it. |